Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Investment analysts at Zacks Research lifted their FY2026 earnings per share estimates for Halozyme Therapeutics in a research report issued to clients and investors on Monday, April 22nd. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings of $5.16 per share for […]
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Research analysts at Leerink Partnrs cut their Q1 2024 earnings estimates for shares of Halozyme Therapeutics in a note issued to investors on Wednesday, April 3rd. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings of $0.58 per share for the quarter, […]
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Research analysts at Zacks Research cut their Q3 2024 earnings per share (EPS) estimates for Halozyme Therapeutics in a research note issued on Thursday, February 1st. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings of $0.87 per share for the quarter, […]